Price
356.6
+0.02%52W Range
Market Cap
₹3,339.63 Cr
Traded: ₹4.62 Cr (0.14%) 0.0x
Free Float: ₹955.13 Cr (0.48% of FF traded)
Volume · 60D trend
1.3 L 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| Profit | +10.0% | +10.0% | +155.0% | -- | +48.0% | Stable |
| Return | +18.0% | +20.0% | +66.0% | +46.0% | -- | Stable |
| ROE | +11.0% | +10.0% | +12.0% | -- | -- | Stable |
| Sales | +4.0% | +10.0% | +19.0% | -- | +13.0% | Stable |
Quarterly Results
Mar 2023
Dec 2022
Sep 2022
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023PDF ↗ | Sep 2023PDF ↗ | Jun 2023PDF ↗ | Mar 2023 | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 207 | 238 | 210 | 242 | 196 | 248 | 173 | 197 | 164 | 246 | 161 | 167 | 135 | 149 | 149 | 159 |
| Expenses | 166 | 198 | 167 | 194 | 157 | 207 | 140 | 165 | 131 | 212 | 132 | 139 | 109 | 126 | 130 | 146 |
| Operating Profit | 41 | 40 | 44 | 48 | 39 | 41 | 33 | 31 | 34 | 34 | 29 | 28 | 26 | 23 | 19 | 14 |
| OPM % | 20.0% | 17.0% | 21.0% | 20.0% | 20.0% | 16.0% | 19.0% | 16.0% | 20.0% | 14.0% | 18.0% | 17.0% | 19.0% | 16.0% | 12.0% | 9.0% |
| Other Income | 2 | 3 | 4 | 1 | 1 | 1 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 2 | 1 |
| Interest | 6 | 5 | 6 | 6 | 6 | 5 | 4 | 5 | 5 | 6 | 6 | 6 | 6 | 6 | 6 | 5 |
| Depreciation | 10 | 10 | 10 | 10 | 10 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 |
| Profit Before Tax | 27 | 27 | 31 | 34 | 24 | 29 | 22 | 20 | 22 | 22 | 17 | 15 | 13 | 11 | 7 | 1 |
| Tax % | 26.0% | 23.0% | 26.0% | 26.0% | 23.0% | 30.0% | 24.0% | 29.0% | 25.0% | 26.0% | 26.0% | 21.0% | 31.0% | 24.0% | 21.0% | 13.0% |
| Net Profit | 21 | 33 | 23 | 25 | 20 | 20 | 18 | 14 | 16 | 17 | 11 | 12 | 9 | 6 | 4 | -2 |
| Exceptional Items | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| EPS (Rs) | 2.2 | 3.5 | 2.5 | 2.7 | 2.3 | 2.3 | 2.1 | 1.7 | 1.9 | 2.0 | 1.4 | 1.4 | 1.1 | 0.7 | 0.4 | -0.2 |
| Sales Growth (YoY) | -- | -4.1% | 21.4% | 23.2% | 19.2% | 1.0% | 7.3% | 18.1% | 21.5% | 64.5% | 8.5% | 4.5% | 110.2% | 144.4% | -- | -- |
| Sales Growth (QoQ) | -- | 13.3% | -13.2% | 23.5% | -21.0% | 43.4% | -12.2% | 20.1% | -33.3% | 52.8% | -3.6% | 23.7% | -9.4% | 0.0% | -6.3% | -- |
| OP Growth (YoY) | 5.1% | -2.4% | 33.3% | 54.8% | 14.7% | 20.6% | 13.8% | 10.7% | 30.8% | 47.8% | 52.6% | 100.0% | -- | -- | -- | -- |
| OP Growth (QoQ) | 2.5% | -9.1% | -8.3% | 23.1% | -4.9% | 24.2% | 6.5% | -8.8% | 0.0% | 17.2% | 3.6% | 7.7% | 13.0% | 21.1% | 35.7% | -- |
| Profit Growth (YoY) | 2.0% | 61.0% | 28.7% | 79.5% | 24.3% | 17.6% | 58.9% | 20.2% | 76.5% | 177.8% | 205.3% | 683.6% | 173.1% | 1.0% | -58.0% | -109.0% |
| EPS Growth (YoY) | -- | 52.4% | 16.7% | 62.6% | 18.5% | 12.3% | 58.1% | 20.3% | 77.3% | 179.4% | 209.1% | 675.0% | -- | -- | -- | -- |
| EPS Growth (QoQ) | -- | 39.0% | -7.0% | 16.9% | 0.9% | 6.5% | 29.5% | -14.9% | -4.4% | 50.0% | -1.4% | 25.4% | 50.7% | 65.9% | 283.3% | -- |
| OP Margin | -- | 16.8% | 20.9% | 19.8% | 19.9% | 16.5% | 19.1% | 15.7% | 20.7% | 13.8% | 18.0% | 16.8% | 19.3% | 15.4% | 12.8% | 8.8% |
| Net Margin | -- | 13.9% | 10.9% | 10.3% | 10.2% | 8.1% | 10.4% | 7.1% | 9.8% | 6.9% | 6.8% | 7.2% | 6.7% | 4.0% | 2.7% | -1.3% |
| Material Cost % | 54.0% | 56.0% | 54.0% | 58.0% | 57.0% | 60.0% | 49.0% | 59.0% | 53.0% | 65.0% | 57.0% | 59.0% | 55.0% | 58.0% | 65.0% | 73.0% |
| Employee Cost % | 11.0% | 12.0% | 10.0% | 8.0% | 9.0% | 11.0% | 11.0% | 9.0% | 10.0% | 8.0% | 9.0% | 9.0% | 10.0% | 10.0% | 9.0% | 8.0% |
| P/S | 3.72 | 3.95 | 4.45 | 4.20 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | 32.63 | 33.96 | 43.41 | 40.76 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 4.25 | 4.46 | 5.47 | 4.95 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50Copy of newspaper publication regarding the 38th Annual General Meeting to be held through VC/ other Audio Visual Means
Please find the enclosure
Fixation of Record date
SMS Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 01/08/2026 ,inter alia, to consider and approve Un-audited Financial Results ....
Please find attached
Copy of Newspaper Publication for information regarding transfer of shares to IEPF.
Certificate under Regulation 74 (5) of SEBI (DP) Regulations, 2018
Clarification on Volume/price movement
The Exchange has sought clarification from SMS Pharmaceuticals Ltd on July 01, 2026, with reference to Movement in Volume. <BR><BR>The reply is awaited.
Closure of Trading Window
Transcripts of the Conference call held on 27th May, 2026
Audio recording of Analysts/Investors Conference Call pertaining to the Financial Results for the fourth quarter and year ended 31st March, 2026
copy of newspaper publication
Investor Presentation
Press Release on Financial Results for the year ended 31.03.2026
Intimation of Investor Call
Please find the enclosure
Please find the enclosure
Re-appointment of Auditors of the Company
Outcome of the Board Meeting for approval of Financial results for the fourth quarter and year ended 31st March, 2026
Please find the enclosure
SMS Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/05/2026 ,inter alia, to consider and approve the audited financial results ....
Monitoring Agency Report for the quarter ended 31st March, 2026
Newspaper Publication regarding " Second 100 days Campaign - Saksham Niveshak
Please refer the enclosed file
Receipt of Rectification order by Income Tax Department
Certificate under Regulation 74 (5) of SEBI (DP) Regulations, 2018
Demand Notice form Income Tax Department
Closure of Trading Window for the quarter and year ended 31st March, 2026.
Copy of Newspaper Publication
Monitoring Agency Report for 31st Dec 2025
Newspaper Publication
Investor Presentation
Press Release on Financial Results
Financial results for the quarter ended 31st December, 2025
Financial Results for the quarter ended 31st December, 2025
Statement of Deviation or variation for the quarter ended December 31, 2025
SMS Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/02/2026 ,inter alia, to consider and approve the Unaudited (Standalone ....
Please find enclosed.
Certificate under 74(5) of SEBI(DP) Regulations for the quarter ended 31st December, 2025
Intimation of closure of trading window for the third quarter ended 31st December, 2025
Investment in Subsidiary Company by way of subscription towards right issue.
Incorporation of wholly owned subsidiary company
Completion of USFDA inspection at vizag manufacturing facility
Intimation of Credit Rating
Press Release
Transcript of the conference call held on 11th November, 2025
Monitoring Agency Report for the quarter ended 30th September, 2025
The Exchange has received revised Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on November 11, 2025 for Hima Bindu Potluri
The Exchange has received revised Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on November 11, 2025 for Hima Bindu Potluri
Annual Reports
15Credit Ratings
6Concalls
20Feb 2026
28 Feb 2026Nov 2025
30 Nov 2025Aug 2025
31 Aug 2025Jun 2025
30 Jun 2025Feb 2025
28 Feb 2025Nov 2024
30 Nov 2024Aug 2024
31 Aug 2024Jun 2024
30 Jun 2024Feb 2024
29 Feb 2024Nov 2023
30 Nov 2023Aug 2023
31 Aug 2023May 2023
31 May 2023Feb 2023
28 Feb 2023Nov 2022
30 Nov 2022Aug 2022
31 Aug 2022Aug 2022
31 Aug 2022Jun 2022
30 Jun 2022Feb 2022
28 Feb 2022Nov 2021
30 Nov 2021Oct 2021
31 Oct 2021Held by ETFs
1 ETFs hold smspharma · sorted by weight
Held by Mutual Funds
2 schemes hold smspharma · sorted by weight